0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy

      research-article
      a , , , a , , a , a , a , a , a , b , a , a ,
      Acta Pharmaceutica Sinica. B
      Elsevier
      FeS-based cascade bioreactor, Glucose oxidase, Tumor penetration, Synergistic therapy, ICD amplifier, Cancer immunotherapy, Metastasis inhibition, ALT, alanine transaminase, ATP, adenosine triphosphate, AST, aspartate aminotransferase, ALP, alkaline phosphatise, BUN, blood urea nitrogen, CDT, chemodynamic therapy, Ce6, Chlorin e6, CLSM, confocal laser scanning microscope, CREA, creatinine, CRT, calreticulin, CTLA-4, cytotoxic T-lymphocyte-associated protein 4, CTLs, cytotoxic T lymphocytes, DAMPs, damage-related molecular patterns, DAPI, 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride, DCs, dendritic cells, DLS, dynamic light scattering, DMPO, dimethyl pyridine N-oxide, EDS, energy-dispersive spectrometry, EPR, enhanced permeability and retention, EDC, 1-ethyl-3-(3ʹ-dimethylaminopropyl) carbodiimide, ESR, electron spin resonance, FG, FeS-GOx nanodots, FGP, FeS-GOx@PTX nanoparticles, FITC, fluorescein Isothiocyanate, FeCl2·4H2O, iron dichloride tetrahydrate, Glu, glucose, GOx, glucose oxidase, H2DCFDA, 2,7-dichlorodihydrofluorescein acetoacetic acid, H&E, hematoxylin and eosin, HMGB-1, high mobility group box protein 1, HSA, human serum albumin, HPF, 2-[6-(4,-hydroxy) phenoxy-3H-xanthene-3-on-9-yl, ICB, immune checkpoint blockade, ICD, immunogenic cell death, IFN-γ, interferon-γ, MB, methylene blue, MCTS, multicellular tumor spheroids, MFI, median fluorescence Intensity, Na2S, sodium sulfide, NHS, N-hydroxy succinimide, OH, hydroxyl, PBS, phosphate buffer saline, PTT, photothermal therapy, PTX, paclitaxel, ROS, reactive oxygen species, SEM, scanning electron microscope, TAA, tumor-associated antigens, TDLN, tumor-draining lymph nodes, TEM, transmission microscope, TMB, 3,3ʹ,5,5ʹ-tetramathylbenzidine, TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling, XPS, X-ray photoelectron spectroscopy, XRD, X-ray diffraction patterns

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Major challenges for cancer treatment are how to effectively eliminate primary tumor and sufficiently induce immunogenic cell death (ICD) to provoke a robust immune response for metastasis control. Here, a self-assembled cascade bioreactor was developed to improve cancer treatment with enhanced tumor penetration and synergistic therapy of starvation, chemodynamic (CDT) and photothermal therapy. Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction. After accumulated at tumor sites, FGP disassembles to smaller FeS-GOx for enhanced deep tumor penetration. GOx maintains high enzymatic activity to catalyze glucose with assistant of oxygen to generate hydrogen peroxide (H 2O 2) as starvation therapy. Fenton reaction involving the regenerated H 2O 2 in turn produced more hydroxyl radicals for enhanced CDT. Following near-infrared laser at 808 nm, FGPs displayed pronounced tumor inhibition in vitro and in vivo by the combination therapy. The consequent increased exposure to calreticulin amplified ICD and promoted dendritic cells maturation. In combination with anti-CTLA4 checkpoint blockade, FGP can absolutely eliminate primary tumor and avidly inhibit distant tumors due to the enhanced intratumoral infiltration of cytotoxic T lymphocytes. Our work presents a promising strategy for primary tumor and metastasis inhibition.

          Graphical abstract

          A self-assembled FeS-based cascade bioreactor was developed to perform deep tumor penetration and synergistic treatments of starvation, chemodynamic and photothermal therapy. It effectively eliminated primary tumor and provoked a robust antitumor immune response for metastasis inhibition.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Immune checkpoint inhibitors: recent progress and potential biomarkers

          Cancer growth and progression are associated with immune suppression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. Monoclonal antibodies that target immune checkpoints provided an immense breakthrough in cancer therapeutics. Among the immune checkpoint inhibitors, PD-1/PD-L1 and CTLA-4 inhibitors showed promising therapeutic outcomes, and some have been approved for certain cancer treatments, while others are under clinical trials. Recent reports have shown that patients with various malignancies benefit from immune checkpoint inhibitor treatment. However, mainstream initiation of immune checkpoint therapy to treat cancers is obstructed by the low response rate and immune-related adverse events in some cancer patients. This has given rise to the need for developing sets of biomarkers that predict the response to immune checkpoint blockade and immune-related adverse events. In this review, we discuss different predictive biomarkers for anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors, including immune cells, PD-L1 overexpression, neoantigens, and genetic and epigenetic signatures. Potential approaches for further developing highly reliable predictive biomarkers should facilitate patient selection for and decision-making related to immune checkpoint inhibitor-based therapies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunogenic cell death and DAMPs in cancer therapy.

            Although it was thought that apoptotic cells, when rapidly phagocytosed, underwent a silent death that did not trigger an immune response, in recent years a new concept of immunogenic cell death (ICD) has emerged. The immunogenic characteristics of ICD are mainly mediated by damage-associated molecular patterns (DAMPs), which include surface-exposed calreticulin (CRT), secreted ATP and released high mobility group protein B1 (HMGB1). Most DAMPs can be recognized by pattern recognition receptors (PRRs). In this Review, we discuss the role of endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in regulating the immunogenicity of dying cancer cells and the effect of therapy-resistant cancer microevolution on ICD.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

              With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.
                Bookmark

                Author and article information

                Contributors
                Journal
                Acta Pharm Sin B
                Acta Pharm Sin B
                Acta Pharmaceutica Sinica. B
                Elsevier
                2211-3835
                2211-3843
                13 May 2021
                October 2021
                13 May 2021
                : 11
                : 10
                : 3244-3261
                Affiliations
                [a ]School of Pharmaceutical Science, Nanjing Tech University, Nanjing 211816, China
                [b ]School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China
                Author notes
                [†]

                These authors made equal contributions to this work.

                Article
                S2211-3835(21)00170-2
                10.1016/j.apsb.2021.05.005
                8546854
                34729313
                33da2905-9889-4edf-af20-ef787be46212
                © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 1 April 2021
                : 28 April 2021
                : 6 May 2021
                Categories
                Original Article

                mb, methylene blue,mcts, multicellular tumor spheroids,mfi, median fluorescence intensity,na2s, sodium sulfide,nhs, n-hydroxy succinimide,oh, hydroxyl,pbs, phosphate buffer saline,ptt, photothermal therapy,ptx, paclitaxel,ros, reactive oxygen species,sem, scanning electron microscope,taa, tumor-associated antigens,tdln, tumor-draining lymph nodes,tem, transmission microscope,tmb, 3,3ʹ,5,5ʹ-tetramathylbenzidine,tunel, terminal deoxynucleotidyl transferase dutp nick end labelling,xps, x-ray photoelectron spectroscopy,xrd, x-ray diffraction patterns,fes-based cascade bioreactor,glucose oxidase,tumor penetration,synergistic therapy,icd amplifier,cancer immunotherapy,metastasis inhibition,alt, alanine transaminase,atp, adenosine triphosphate,ast, aspartate aminotransferase,alp, alkaline phosphatise,bun, blood urea nitrogen,cdt, chemodynamic therapy,ce6, chlorin e6,clsm, confocal laser scanning microscope,crea, creatinine,crt, calreticulin,ctla-4, cytotoxic t-lymphocyte-associated protein 4,ctls, cytotoxic t lymphocytes,damps, damage-related molecular patterns,dapi, 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride,dcs, dendritic cells,dls, dynamic light scattering,dmpo, dimethyl pyridine n-oxide,eds, energy-dispersive spectrometry,epr, enhanced permeability and retention,edc, 1-ethyl-3-(3ʹ-dimethylaminopropyl) carbodiimide,esr, electron spin resonance,fg, fes-gox nanodots,fgp, fes-gox@ptx nanoparticles,fitc, fluorescein isothiocyanate,fecl2·4h2o, iron dichloride tetrahydrate,glu, glucose,gox, glucose oxidase,h2dcfda, 2,7-dichlorodihydrofluorescein acetoacetic acid,h&e, hematoxylin and eosin,hmgb-1, high mobility group box protein 1,hsa, human serum albumin,hpf, 2-[6-(4,-hydroxy) phenoxy-3h-xanthene-3-on-9-yl,icb, immune checkpoint blockade,icd, immunogenic cell death,ifn-γ, interferon-γ
                mb, methylene blue, mcts, multicellular tumor spheroids, mfi, median fluorescence intensity, na2s, sodium sulfide, nhs, n-hydroxy succinimide, oh, hydroxyl, pbs, phosphate buffer saline, ptt, photothermal therapy, ptx, paclitaxel, ros, reactive oxygen species, sem, scanning electron microscope, taa, tumor-associated antigens, tdln, tumor-draining lymph nodes, tem, transmission microscope, tmb, 3,3ʹ,5,5ʹ-tetramathylbenzidine, tunel, terminal deoxynucleotidyl transferase dutp nick end labelling, xps, x-ray photoelectron spectroscopy, xrd, x-ray diffraction patterns, fes-based cascade bioreactor, glucose oxidase, tumor penetration, synergistic therapy, icd amplifier, cancer immunotherapy, metastasis inhibition, alt, alanine transaminase, atp, adenosine triphosphate, ast, aspartate aminotransferase, alp, alkaline phosphatise, bun, blood urea nitrogen, cdt, chemodynamic therapy, ce6, chlorin e6, clsm, confocal laser scanning microscope, crea, creatinine, crt, calreticulin, ctla-4, cytotoxic t-lymphocyte-associated protein 4, ctls, cytotoxic t lymphocytes, damps, damage-related molecular patterns, dapi, 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride, dcs, dendritic cells, dls, dynamic light scattering, dmpo, dimethyl pyridine n-oxide, eds, energy-dispersive spectrometry, epr, enhanced permeability and retention, edc, 1-ethyl-3-(3ʹ-dimethylaminopropyl) carbodiimide, esr, electron spin resonance, fg, fes-gox nanodots, fgp, fes-gox@ptx nanoparticles, fitc, fluorescein isothiocyanate, fecl2·4h2o, iron dichloride tetrahydrate, glu, glucose, gox, glucose oxidase, h2dcfda, 2,7-dichlorodihydrofluorescein acetoacetic acid, h&e, hematoxylin and eosin, hmgb-1, high mobility group box protein 1, hsa, human serum albumin, hpf, 2-[6-(4,-hydroxy) phenoxy-3h-xanthene-3-on-9-yl, icb, immune checkpoint blockade, icd, immunogenic cell death, ifn-γ, interferon-γ

                Comments

                Comment on this article